Vertex Pharmaceuticals Inc (VRTX)
422.82
+3.83
(+0.91%)
USD |
NASDAQ |
May 10, 16:00
422.82
0.00 (0.00%)
After-Hours: 20:00
Vertex Pharmaceuticals Free Cash Flow: 3.479B for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
March 31, 2024 | 3.479B |
December 31, 2023 | 3.279B |
September 30, 2023 | 4.205B |
June 30, 2023 | 3.879B |
March 31, 2023 | 3.890B |
December 31, 2022 | 3.925B |
September 30, 2022 | 3.814B |
June 30, 2022 | 3.787B |
March 31, 2022 | 2.451B |
December 31, 2021 | 2.408B |
September 30, 2021 | 1.919B |
June 30, 2021 | 1.777B |
March 31, 2021 | 3.048B |
December 31, 2020 | 2.994B |
September 30, 2020 | 2.979B |
June 30, 2020 | 2.557B |
March 31, 2020 | 1.983B |
December 31, 2019 | 1.494B |
September 30, 2019 | 1.364B |
June 30, 2019 | 1.414B |
March 31, 2019 | 1.258B |
December 31, 2018 | 1.175B |
September 30, 2018 | 1.060B |
June 30, 2018 | 682.12M |
March 31, 2018 | 554.31M |
Date | Value |
---|---|
December 31, 2017 | 585.52M |
September 30, 2017 | 530.93M |
June 30, 2017 | 600.58M |
March 31, 2017 | 461.24M |
December 31, 2016 | 179.54M |
September 30, 2016 | 66.22M |
June 30, 2016 | -56.42M |
March 31, 2016 | -205.05M |
December 31, 2015 | -410.73M |
September 30, 2015 | -623.81M |
June 30, 2015 | -649.88M |
March 31, 2015 | -665.82M |
December 31, 2014 | -624.31M |
September 30, 2014 | -422.57M |
June 30, 2014 | -357.86M |
March 31, 2014 | -220.96M |
December 31, 2013 | -112.06M |
September 30, 2013 | -104.83M |
June 30, 2013 | 11.96M |
March 31, 2013 | 117.56M |
December 31, 2012 | 196.70M |
September 30, 2012 | 738.52M |
June 30, 2012 | 686.87M |
March 31, 2012 | 297.38M |
December 31, 2011 | 109.14M |
Free Cash Flow Range, Past 5 Years
1.364B
Minimum
Sep 2019
4.205B
Maximum
Sep 2023
2.832B
Average
2.986B
Median
Free Cash Flow Benchmarks
Amgen Inc | 7.098B |
Eli Lilly and Co | -3.896B |
Regeneron Pharmaceuticals Inc | 3.930B |
Alpine Immune Sciences Inc | -79.50M |
Editas Medicine Inc | -151.03M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | 1.307B |
Cash from Investing (Quarterly) | -2.136B |
Cash from Financing (Quarterly) | -357.50M |
Free Cash Flow Per Share (Quarterly) | 4.053 |
Free Cash Flow to Equity (Quarterly) | 1.058B |
Free Cash Flow to Firm (Quarterly) | 1.058B |
Free Cash Flow Yield | 3.16% |